Of Interest

Dr In on the Safety and Efficacy of RP1 in Patients With Melanoma Post–PD-1 Inhibitor Progression

Gino Kim In, MD, a medical oncologist, Medical Oncology, Melanoma Surgery, Sarcoma and Melanoma Surgery and associate professor of clinical medicine at Keck School of Medicine of the University of Southern California, discussed the safety and efficacy of superficial and deep or visceral vusolimogene oderparepvec (RP1) injection in a registrational cohort of patients from the phase 3 IGNYTE trial (NCT03767348) with melanoma who progressed on anti–PD-1 inhibitors.

Read More
MRV News
Melanoma News
Archive
Menu